María Herrero-Zazo

Learn More
The DDIExtraction 2013 task concerns the recognition of drugs and extraction of drugdrug interactions that appear in biomedical literature. We propose two subtasks for the DDIExtraction 2013 Shared Task challenge: 1) the recognition and classification of drug names and 2) the extraction and classification of their interactions. Both subtasks have been very(More)
The management of drug-drug interactions (DDIs) is a critical issue resulting from the overwhelming amount of information available on them. Natural Language Processing (NLP) techniques can provide an interesting way to reduce the time spent by healthcare professionals on reviewing biomedical literature. However, NLP techniques rely mostly on the(More)
The DDIExtraction Shared Task 2013 is the second edition of the DDIExtraction Shared Task series, a community-wide effort to promote the implementation and comparative assessment of natural language processing (NLP) techniques in the field of the pharmacovigilance domain, in particular, to address the extraction of drug-drug interactions (DDI) from(More)
Drug-drug interactions form a significant risk group for adverse effects associated with pharmaceutical treatment. These interactions are often reported in the literature, however, they are sparsely represented in machine-readable resources, such as online databases, thesauri or ontologies. These knowledge sources play a pivotal role in Natural Language(More)
The early detection of drug-drug interactions (DDIs) is limited by the diffuse spread of DDI information in heterogeneous sources. Computational methods promise to play a key role in the identification and explanation of DDIs on a large scale. However, such methods rely on the availability of computable representations describing the relevant domain(More)
Artificial neural networks (ANNs) have been developed to predict the clinical significance of drug-drug interactions (DDIs) for a set of 35 pharmaceutical drugs using data compiled from the Web-based resources, Lexicomp® and Vidal®, with inputs furnished by various drug pharmacokinetic (PK) and/or pharmacodynamic (PD) properties, and/or drug-enzyme(More)
  • 1